You are viewing the site in preview mode
Skip to main content
| |
ZUMA-1 (axi-cel)
|
TRANSCEND (liso-cel)
|
Liso-cel versus axi-cel
|
|---|
|
N (%)
|
Median (95% CI), mo
|
N/ESS
|
Median (95% CI), mo
|
HR (95% CI)
|
P
|
|---|
|
PFS
|
|
Naïve comparison
|
101
|
5.8 (3.4–15.0)*
|
256
|
4.1 (3.0–6.0)
|
1.20 (0.90–1.59)
|
0.219
|
|
Initial analysis
| | |
40.0
|
6.3 (3.0–NR)
|
0.95 (0.58–1.57)
|
0.847
|
|
Sensitivity analysis 1
| | |
151.4
|
3.5 (3.0–5.9)
|
1.30 (0.96–1.77)
|
0.095
|
|
Sensitivity analysis 2
| | |
98.9
|
5.0 (3.0–9.2)
|
1.16 (0.81–1.66)
|
0.408
|
|
OS
|
|
Naïve comparison
|
101
|
NR (12.8–NR)*
|
256
|
21.1 (13.3–NR)
|
1.13 (0.81–1.58)
|
0.457
|
|
Initial analysis
| | |
38.3
|
NR (11.6–NR)
|
0.81 (0.44–1.49)
|
0.506
|
|
Sensitivity analysis 1
| | |
152.6
|
19.9 (12.1–NR)
|
1.15 (0.80–1.65)
|
0.454
|
|
Sensitivity analysis 2
| | |
98.9
|
21.1 (14.4–NR)
|
1.04 (0.70–1.56)
|
0.838
|
- Axi-cel, axicabtagene ciloleucel; CI, confidence interval; ESS, effective sample size; HR, hazard ratio; liso-cel, lisocabtagene maraleucel; N, sample size; NR, not reached; OS, overall survival; PFS, progression-free survival
- *The median was obtained from pseudo-individual patient data based on a digitized Kaplan–Meier curve [16]
